ArticleArchives of Razi Institute2024
Ameliorative Potential of Resveratrol on Kidney Toxicities Following Adjuvant Treatment with Antiretroviral Drugs in Male Wistar Rats.
Article in Archives of Razi Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prolonged use of antiretroviral agents has been clearly associated with nephrotoxicity, suggesting deterioration of renal function in patients receiving Highly Active Antiretroviral Therapy (HAART). The present study was designed to investigate the therapeutic efficacy of resveratrol (RV) in the treatment toxins-induced renal impairment. Twenty-four adult male Wistar rats weighing 70-90 g were divided into four groups and subjected to the following treatments: Control A (distilled water), B (HAART), C (RV-2.5 mg/kg), D (RV- 2.5 mg/kg) + HAART. Assessment included renal histological examination; renal function indicators such as serum creatinine and blood urea nitrogen; serum electrolyte levels including sodium, chloride, potassium, bicarbonate; and oxidative stress biomarkers such as malondialdehyde, catalase and glutathione and superoxide dismutase. Adverse effects of HAART include adverse histological changes, such as tubular atrophy, vacuolization, tubular granular degeneration and glomerular capillaries abnormalities. Compared to the other treatment cohorts, serum creatinine, blood urea nitrogen (BUN), sodium, chloride and malondialdehyde (MDA) levels were significantly increased, while antioxidant enzyme activities such as catalase (CAT) and superoxide dismutase (SOD) and glutathione (GSH) levels were notably decreased. Renal structure remained largely unchanged after RV administration, with some recovery in histological abnormalities. Visible improvements, including reduced inflammation, reduced necrosis, reduced vacuolization and improved tubule and glomerular configuration, were also observed. In addition, RV notably increased antioxidant enzyme levels (SOD, CAT, and GSH) and decreased BUN, serum creatinine and MDA levels. RV helped mitigate HAART-induced structural abnormalities and renal dysfunction, while improving renal morphology. However, further investigation of these mechanisms is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.